13 junio 2016

JOURNAL OF THE AMERICAN HEART ASSOCIATION. Interventional Cardiology. Transcatheter Aortic Valve Implantation With or Without Preimplantation Balloon Aortic Valvuloplasty: A Systematic Review and Meta‐Analysis

Rodrigo Bagur, MD, PhD, FAHA*,1,2; Chun Shing Kwok, BSc, MBBS, MSc, MRCP4,5; Luis Nombela‐Franco, MD, PhD6; Peter F. Ludman, MD, FRCP, FESC7; Mark A. de Belder, MD, FRCP8; Sandro Sponga, MD, PhD9; Mark Gunning, MD4; James Nolan, MD4; Pantelis Diamantouros, MD, FRCPC1; Patrick J. Teefy, MD, FRCPC1; Bob Kiaii, MD, FRCSC3,10; Michael W. A. Chu, MD, FRCSC3,10; Mamas A. Mamas, BMBCh, DPhil, MRCP4,5

Background: Preimplantation balloon aortic valvuloplasty (BAV) is considered a routine procedure during transcatheter aortic valve implantation (TAVI) to facilitate prosthesis implantation and expansion; however, it has been speculated that fewer embolic events and/or less hemodynamic instability may occur if TAVI is performed without preimplantation BAV. The aim of this study was to systematically review the clinical outcomes associated with TAVI undertaken without preimplantation BAV.

27 junio 2016

JOURNAL OF THE AMERICAN HEART ASSOCIATION. Interventional Cardiology. Outcome of 1051 Octogenarian Patients With ST‐Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Observational Cohort From the London Heart Attack Group

Daniel I. Bromage, MD9; Daniel A. Jones, MD1; Krishnaraj S. Rathod, MD1; Claire Grout, MD1; M. Bilal Iqbal, MD2; Pitt Lim, MD3; Ajay Jain, MD1; Sundeep S. Kalra, MD5; Tom Crake, MD4; Zoe Astroulakis, MD3; Mick Ozkor, MD4; Roby D. Rakhit, MD6; Charles J. Knight, MD1; Miles C. Dalby, MD2; Iqbal S. Malik, MD7; Anthony Mathur, MD1; Simon Redwood, MD8; Philip A. MacCarthy, MD5; Andrew Wragg, MD*,1

Background: ST‐segment elevation myocardial infarction is increasingly common in octogenarians, and optimal management in this cohort is uncertain. This study aimed to describe the outcomes of octogenarians with ST‐segment elevation myocardial infarction treated by primary percutaneous coronary intervention.

15 julio 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Artery Disease. The EBC TWO Study (European Bifurcation Coronary TWO). A Randomized Comparison of Provisional T-Stenting Versus a Systematic 2 Stent Culotte Strategy in Large Caliber True Bifurcations

David Hildick-Smith, MD, FRCP, Miles W. Behan, DM, FRCP, Jens F. Lassen, MD, Alaide Chieffo, MD, Thierry Lefèvre, MD, Goran Stankovic, MD, Francesco Burzotta, MD, Manuel Pan, MD, Miroslaw Ferenc, MD, Lorraine Bennett, MSc, Thomas Hovasse, MD, Mark S. Spence, MD, FRCP, Keith Oldroyd, MD, FRCP, Philippe Brunel, MD, Didier Carrie, MD, Andreas Baumbach, MD, FRCP, Michael Maeng, MD, Nicola Skipper, MSc and Yves Louvard, MD

Background: For the treatment of coronary bifurcation lesions, a provisional strategy is superior to systematic 2-stent techniques for the most bifurcation lesions. However, complex anatomies with large side branches (SBs) with significant ostial disease length are considered by expert consensus to warrant a 2-stent technique upfront. This consensus view has not been scientifically assessed.

02 agosto 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Validation of the Coronary Artery Bypass Graft SYNTAX Score (Synergy Between Percutaneous Coronary Intervention With Taxus) as a Prognostic Marker for Patients With Previous Coronary Artery Bypass Graft Surgery After Percutaneous Coronary Intervention

Tadayoshi Miyagi, MD, Yasuhide Asaumi, MD, PhD, Kunihiro Nishimura, MD, PhD, Takahiro Nakashima, MD, Hiroki Sakamoto, MD, Kazuhiro Nakao, MD, Tomoaki Kanaya, MD, Toshiyuki Nagai, MD, PhD, Yuji Shimabukuro, MD, Yoshihiro Miyamoto, MD, PhD, Tomoyuki Fujita, MD, PhD, Kengo Kusano, MD, PhD, Toshihisa Anzai, MD, PhD, Junjirou Kobayashi, MD, PhD, Teruo Noguchi, MD, PhD, Hisao Ogawa, MD, PhD and Satoshi Yasuda, MD, PhD

Background: The efficacy and prognosis of percutaneous coronary intervention (PCI) as secondary revascularization in patients with previous coronary artery bypass graft surgery remain uncertain.

23 junio 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Incidence, Determinants, and Outcomes of Coronary Perforation During Percutaneous Coronary Intervention in the United Kingdom Between 2006 and 2013. An Analysis of 527 121 Cases From the British Cardiovascular Intervention Society Database

Tim Kinnaird, MD, Chun Shing Kwok, MBBS, MSc, BSc, Evangelos Kontopantelis, PhD, Nicholas Ossei-Gerning, MD, Peter Ludman, MD, Mark deBelder, MD, Richard Anderson, MD and Mamas A. Mamas, MADPhil; on behalf of the British Cardiovascular Intervention Society and the National Institute for Cardiovascular Outcomes Research

Background—As coronary perforation (CP) is a rare but serious complication of percutaneous coronary intervention (PCI) the current evidence base is limited to small series. Using a national PCI database, the incidence, predictors, and outcomes of CP as a complication of PCI were defined.

23 junio 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents

Salvatore Cassese, MD, PhD, Petra Hoppmann, MD, Sebastian Kufner, MD, Robert A. Byrne, MB, BCh, PhD, Jens Wiebe, MD, Roisin Colleran, MB, BCh, Daniele Giacoppo, MD, Yukinori Harada, MD, Karl-Ludwig Laugwitz, MD, Heribert Schunkert,, MD, Massimiliano Fusaro, MD and Adnan Kastrati, MD

Background: The performance of everolimus-eluting bioresorbable vascular scaffold (BVS) versus drug-eluting metallic stent (DES) in the same individual receiving multilesion percutaneous coronary intervention (PCI) remains poorly studied. This report investigates the intraindividual performance of BVS and DES in patients receiving multilesion PCI and follow-up angiography.

06 julio 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Cardiac Catheterization. Allergic Inflammation Is Associated With Coronary Instability and a Worse Clinical Outcome After Acute Myocardial Infarction

Giampaolo Niccoli, MD, PhD, Camilla Calvieri, MD, Davide Flego, MD, Giancarla Scalone, MD, Asya Imaeva, MD, Vito Sabato, MD, Domenico Schiavino, MD, Giovanna Liuzzo, MD and Filippo Crea, MD, PhD

Background: The role of allergic inflammation in acute coronary syndromes (ACS) has not been clearly defined to date. Aim of this study was to assess eosinophil and basophil activation in ACS and the prognostic role of eosinophil cationic protein in ST-segment–elevation myocardial infarction.

30 marzo 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Advances in Interventional Cardiology. Techniques and Outcomes for the Treatment of Paravalvular Leak

Mackram F. Eleid, MD, Allison K. Cabalka, MD, Joseph F. Malouf, MD, Saurabh Sanon, MBBS, Donald J. Hagler, MD and Charanjit S. Rihal, MD, MBA

Paravalvular prosthetic regurgitation is a potentially serious condition resulting from degeneration of annular tissue, affecting 6% to 15% of surgically implanted prosthetic valves and annuloplasty rings.1–3 In conditions of tissue friability from any cause, annular calcification, or infection, paravalvular defects can form and lead to varying degrees of regurgitation. Surgical factors associated with the development of paravalvular regurgitation include prostheses in the mitral position, supra-annular aortic prostheses, use of continuous sutures in the mitral position,3 and use of sutures without pledgets.

25 junio 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Images and Case Reports in Interventional Cardiology. Fracturing the Ring of Small Mitroflow Bioprostheses by High-Pressure Balloon Predilatation in Transcatheter Aortic Valve-in-Valve Implantation

Jens Erik Nielsen-Kudsk, MD, DMSc, Evald Høj Christiansen, MD, PhD, Christian Juhl Terkelsen, MD, DMSc, Bjarne Linde Nørgaard, MD, PhD, Kaare Troels Jensen, MD, PhD, Lars Romer Krusell, MD, Mariann Tang, MD, Kim Terp, MD, Kaj-Erik Klaaborg, MD and Henning Rud Andersen, MD, DMSc

Introduction: Early deterioration of Mitroflow aortic bioprostheses (Sorin Group Inc), particularly small sizes 19 and 21 mm, has been reported.1 Treatment of failing bioprostheses by transcatheter valve-in-valve (VIV) therapy has become an alternative to repeat surgery.2,3 However, VIV treatment is problematic with small surgical bioprostheses because of a further reduction in the effective valve orifice. One way to overcome this challenge may be to fracture the ring of the surgical valve by high-pressure balloon dilatation before implanting a larger size transcatheter valve.

21 julio 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Structural Heart Disease. Effect of Clinical Trial Experience on Transcatheter Aortic Valve Replacement Outcomes

Fenton H. McCarthy, MD, MS, Peter W. Groeneveld, MD, MS, Dale Kobrin, BA, Katherine M. McDermott, BS, Christopher Wirtalla, BA and Nimesh D. Desai, MD, PhD

Background: Transcatheter aortic valve replacement (TAVR) was approved by the Food and Drug Administration (FDA) in November 2011 after a collaborative technology development process involving professional medical societies, the medical device industry, and the FDA. After FDA approval, TAVR was adopted by numerous hospitals that had not participated in TAVR clinical trials. It is uncertain if outcomes at these hospitals were comparable with those at clinical trial hospitals.

17 agosto 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Myocardial Infarction. Direct Transfer From the Referring Hospitals to the Catheterization Laboratory to Minimize Reperfusion Delays for Primary Percutaneous Coronary Intervention. Insights From the National Cardiovascular Data Registry

Lindsay L Anderson, MD, William J French, MD, S. Andrew Peng, MS, Amit N Vora, MD, MPH, Timothy D Henry, MD, Matthew T Roe, MD, MHS, Michael C Kontos, MD, Christopher B Granger, MD, Eric R Bates, MD, Anne Hellkamp, MS and Tracy Y Wang, MD, MHS, MSc

Background: For patients with ST-segment–elevation myocardial infarction (STEMI) requiring interhospital transfer for primary percutaneous coronary intervention, direct transfer from the STEMI referral hospital to the catheterization laboratory (cath lab) at the STEMI receiving hospital may expedite reperfusion, but can be logistically challenging.

31 julio 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Prediction of Cardiac and Noncardiac Mortality After Percutaneous Coronary Intervention

Daniel B. Spoon, MD*, Ryan J. Lennon, MS*, Peter J. Psaltis, MBBS, PhD, Abhiram Prasad, MD, David R. Holmes Jr, MD, Amir Lerman, MD, Charanjit S. Rihal, MD, Bernard J. Gersh, MB ChB, DPhil, Henry H. Ting, MD, Mandeep Singh, MD and Rajiv Gulati, MD, PhD

Background: Current risk models for predicting long-term mortality after percutaneous coronary intervention are restricted to all-cause mortality. We sought to develop novel risk models for the prediction of cardiac and noncardiac mortality after percutaneous coronary intervention.

01 septiembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Hybrid Strategy for Long Diffuse Coronary Lesion

Sandeep Basavarajaiah, MD; Mamoon Qadir, MD

A 48-year-old man with crescendo angina exhibited a severe diffuse lesion in the left anterior descending artery (Figure 1, Online Video). The option of mammary grafting was ruled out due to poor distal target. Percutaneous coronary intervention with drug-eluting stents (DES) would result in full-metal jacket (>50 mm of overlapping stents), which poses the long-term risk of stent thrombosis, and, in addition, restenosis is often difficult to treat, with high rates of recurrence.

01 septiembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Transapical Mitral Valve Implantation for the Treatment of Severe Native Mitral Valve Stenosis in a Prohibitive Surgical Risk Patient. Importance of Comprehensive Cardiac Computed Tomography Procedural Planning

Guilherme F. Attizzani, MD; Anas Fares, MD; Chor Cheung Tam, MD; Bimal Padaliya, MD; Stacey Mazzurco, RN; Kehllee L. Popovich, NP; Angela C. Davis, RN; Elizabeth Staunton, NP; Hiram G. Bezerra, MD, PhD; Alan Markowitz, MD; Daniel I. Simon, MD; Marco A. Costa, MD, PhD; Basar Sareyyupoglu, MD

A 66-year-old woman with severe mitral stenosis (mean gradient, 13.81 mm Hg; valve area, 0.8 cm2) and extensive mitral annular calcification (MAC) presented with New York Heart Association functional class IV congestive heart failure. Balloon mitral valvuloplasty was not considered due to the high Wilkins score (i.e., 12) Because of a Society of Thoracic Surgeons mortality score of 10.04% and cirrhosis (Child-Pugh B), the heart team deemed her at prohibitive surgical risk.

01 septiembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Repeat MitraClip Therapy for Significant Recurrent Mitral Regurgitation in High Surgical Risk Patients. Impact of Loss of Leaflet Insertion

Felix Kreidel, MD∗; Christian Frerker, MD∗; Michael Schlüter, PhD†; Hannes Alessandrini, MD∗; Thomas Thielsen, MD∗; Stephan Geidel, MD‡; Ulrich Schäfer, MD∗; Karl-Heinz Kuck, MD∗

Objectives: The goal of this study was to assess procedural details and outcomes of repeat MitraClip therapy.